Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
obesity drugs
Biotech
Lilly’s triple-G drug drives deep weight loss in phase 3 trial
As Lilly looks to hold its lead in the lucrative obesity market, the company's next-gen prospect met the mark in its first dedicated obesity study.
Nick Paul Taylor
May 21, 2026 10:27am
Wave crashes after obesity trial tracks 1% dip in body weight
Mar 26, 2026 9:20am
Ascletis eyes quarterly GLP-1 dosing following phase 2 readout
Mar 10, 2026 8:20am
Regeneron's obesity drug shows Zepbound-like efficacy in phase 3
Mar 9, 2026 8:25am
Zealand's Zupreme serves up to 10.7% mean weight loss
Mar 5, 2026 4:44pm
How GLP-1s help the heart relax: study
Mar 2, 2026 7:01pm
